Meta Diabetic gives a comprehensive evaluation of sugar metabolism by simultaneously measuring 5 different sugar and sugar alcohol levels.
Meta Adult measures more than 100 metabolites across a total of 9 panels; amino acids, carbohydrates, fatty acids, TCA cycle, nucleic acids, lirea cycle, neuro transmitters, vitamins and drug safety.
Meta Child is a non-invasive screening test for the detection of more than 140 types of severe and fatal metabolic disorders such as inborn errors of metabolism and IEMs in newborn babies. The report reflects the levels of amino acids, carbohydrates, fatty acids and other metabolites.
Now included in the International Clinical Practice Guidelines, Prosigna by Nanostring detects early stage breast cancer in patients through a highly accurate, FDA-approved risk assessment test. With the use of the PAM50 gene signature to translate tumour biology into a patient’s individualised prognostic score, Prosigna also identifies the patient’s 10-year risk of distant recurrence and intrinsic molecular subtype.
ProDetect™ is a series of tests by Medical Innovation Ventures (Mediven) that screens for viruses, drug presence, antigens and antibodies. The tests under the ProDetect™ brand include:
- ProDetect™ Dengue Duo NS1 Ag & IgG/IgM Rapid Test
- ProDetect™ Rotavirus Rapid Test
- ProDetect™ Flu A & B Rapid Test
- ProDetect™ Drug Of Abuse Test
Established to provide a comprehensive and cost-effective solution tailored into patients’ everyday clinical care, OneOme is a genetic test that predicts how a patient’s DNA and prescriptions may affect their response to medication. The test covers medical conditions such as psychiatric conditions, cancer, chronic pain, cardiovascular disease, and more.
GoExplore™ by Genome.One is a genetic test that assesses an individual’s risks to certain inherited conditions that can be treated, managed, monitored or prevented. Based on the results, clinical professionals will provide personalised, professional consults to best manage patients’ health.
The EGFR Mutation Analysis, also known as the Epidermal Growth Factor Receptor Mutation Analysis, helps guide treatment and determines if an individual with lung cancer will respond to targeted therapy and subsequently, what type of therapy will likely be of most benefit. The analysis singles out specific activating mutations in the EGFR gene found in DNA cells in tumour tissue which can lead to uncontrolled growth of cancer cells.
Validated in a CAP-accredited and CLIA-certified lab using Next Generation Sequencing methods, the test is a cancer diagnostic tool that gives a comprehensive analysis of 30 genes associated with the most common hereditary cancers: breast, colorectal, melanoma, pancreatic, prostate, ovarian, stomach and uterine. Reports integrate guidelines to assist in the development of personalised screening and prevention plans for patients. The product has performed blinded validation studies and all genetic variants were detected with >99% accuracy.
Exclusively performed by SAM Clinical Laboratory in Southeast Asia, the Cellsearch® (CTC) Test is the only FDA-approved test for enumerating CTCs. It is an actionable test that assists healthcare professionals in the assessment of patients with metastatic breast, prostate or colorectal cancer.